SMALL CELL LUNG CARCINOMA

This study is for people with small cell or non-small cell lung cancer whose cancer has worsened after initial treatment. It tests a combination of three drugs: ADI-PEG 20, gemcitabine, and docetaxel. The first part finds the safest dose, and the second part checks how well the c…

This study tested the drug pembrolizumab in over 1,600 people with various advanced solid tumors that had stopped responding to standard treatments. The goal was to see if the drug could shrink or control the tumors. The trial focused on identifying which patients were most likel…

This early-stage study tests the safety and tolerability of tarlatamab in about 269 adults with small cell lung cancer that has come back or not responded to standard platinum-based chemotherapy. The main goal is to find the best dose and check for side effects. This is not a cur…

This study tests whether adding tiragolumab to standard atezolizumab plus chemotherapy helps people with untreated extensive-stage small cell lung cancer live longer without their cancer growing. About 123 adults in China are participating. The goal is to see if the new combinati…

This study follows about 254 adults with extensive-stage small cell lung cancer who are getting durvalumab (an immunotherapy) plus standard chemotherapy as their first treatment. Researchers want to see how long patients stay on treatment and how long they live in real-world sett…

This study tests whether the drug durvalumab can help keep cancer from growing in frail patients with limited-stage small cell lung cancer who have already completed chemotherapy and radiation. About 100 participants will receive durvalumab every 4 weeks. The goal is to see if th…